Perspective Therapeutics Inc [CATX] stock is trading at $4.83, down -0.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CATX shares have gain 36.06% over the last week, with a monthly amount glided 38.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Perspective Therapeutics Inc [AMEX: CATX] stock has seen the most recent analyst activity on October 10, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $14. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 13, 2025, and set its price target to $10. On March 07, 2025, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $15 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $5 on November 25, 2024. UBS initiated its recommendation with a Buy and recommended $20 as its price target on October 24, 2024. Wedbush started tracking with a Outperform rating for this stock on October 01, 2024, and assigned it a price target of $25. In a note dated September 25, 2024, Truist initiated an Buy rating and provided a target price of $21 on this stock.
Perspective Therapeutics Inc [CATX] stock has fluctuated between $1.60 and $13.19 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Perspective Therapeutics Inc [AMEX: CATX] shares were valued at $4.83 at the most recent close of the market. An investor can expect a potential return of 189.86% based on the average CATX price forecast.
Analyzing the CATX fundamentals
Perspective Therapeutics Inc [AMEX:CATX] reported sales of 1.24M for the trailing twelve months, which represents a drop of -44.87%. Gross Profit Margin for this corporation currently stands at -1.5% with Operating Profit Margin at -184.63%, Pretax Profit Margin comes in at -204.47%, and Net Profit Margin reading is -197.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.39 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Perspective Therapeutics Inc’s Current Ratio is 15.09. Further, the Quick Ratio stands at 15.09, while the Cash Ratio is 2.22. Considering the valuation of this stock, the price to sales ratio is 289.27, the price to book ratio is 1.35.
Transactions by insiders
Recent insider trading involved Spoor Johan M., Chief Executive Officer, that happened on Mar 28 ’25 when 22026.0 shares were purchased. Chief Executive Officer, Spoor Johan M. completed a deal on Mar 28 ’25 to buy 4650.0 shares. Meanwhile, Director Williamson Robert F III bought 38145.0 shares on Mar 31 ’25.
